Table 2. Physician Examination Reactogenicity in the 7 Days Following Dose 1 and Dose 2 of Vaccine Pooled Data.

	After Dose 1				After Dose 2
	Treatment Group				Treatment Group
Dose	Placebo	15 μg x 2	30 μg x 1	30 μg x 2	Placebo	15 μg x 2	30 μg x 1	30 μg x 2
N	52 (%)	25 (%)	51 (%)	48 (%)	52 (%)	25 (%)	51 (%)	48 (%)
Nasal mucosal inflammation	0	0	0	0	1 (1.9)	0	0	1 (2.0)
Nasal discharge	7 (13.4)	1 (4.0)	9 (17.6)	10 (20.8)	5 (10.4)	3 (12.0)	7 (13.7)	9 (18.7)
Pharyngeal inflammation	4 (7.6)	0	1 (1.9)	1 (2.0)	1 (1.9)	0	2 (3.9)	2 (3.9)
Sinusitis	0	0	0	0	0	0	1 (1.9)	0
Cervical/ Post-auricular nodes	10 (19.2)	0	7 (13.7)	10 (20.8)	8 (15.3)	1 (4.0)	13 (25.4)	10 (20.8)
Otic inflammation	1 (1.9)	0	0	0	2 (3.8)	2 (8.0)	3 (5.8)	2 (3.9)